Form D · Other Technology
Bioverge, Inc.
San Francisco, CA · CIK 0001828649
Offering snapshot reported May 8, 2023 · SEC filing
- Reported sold
- $149K Offering amount: $149K
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Mar 7, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 8, 2023 | Initial | $148,500 | No comparison | 4 | SEC filing |
| May 5, 2023 | Initial | $775,000 | No comparison | 21 | SEC filing |
| May 4, 2023 | Initial | $588,500 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-481032
SAFE Notes
Source: Form D, filed May 8, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Gibb | Executive |
| Neil Littman | Director, Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
447 Sutter St. Ste 405
San Francisco, CA, 94108
San Francisco, CA, 94108